Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04254549 · ClinicalTrials.gov registry record · Phase 2
Rifaximin in Patients With Diabetic Gastroparesis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04254549: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04254549 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04254549, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Primary Outcome
Change is the self reported bloating questionnaire comprised of 45 questions addressing symptoms of bloating/distention. Questionnaires used are the Quality of Life SF-36v2 Survey, Gastroparesis Cardinal Symptom Index Daily Diary, Hospital Anxiety and Depression Scale, and Nepean Dyspepsia Index.
Interventions
- DRUG Placebo
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 2 |
Why NCT04254549 stopped before completion
NCT04254549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04254549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04254549 about?
NCT04254549 is a clinical study titled "Rifaximin in Patients With Diabetic Gastroparesis". Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
What is the current status of trial NCT04254549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-06-14. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT04254549?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT04254549?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04254549's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI